Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation

J Lipid Res. 2015 Jun;56(6):1206-21. doi: 10.1194/jlr.M059485. Epub 2015 Apr 10.

Abstract

Lipolytic modification of LDL particles by SMase generates LDL aggregates with a strong affinity for human arterial proteoglycans and may so enhance LDL retention in the arterial wall. Here, we evaluated the effects of apoA-I mimetic peptide 4F on structural and functional properties of the SMase-modified LDL particles. LDL particles with and without 4F were incubated with SMase, after which their aggregation, structure, and proteoglycan binding were analyzed. At a molar ratio of L-4F to apoB-100 of 2.5 to 20:1, 4F dose-dependently inhibited SMase-induced LDL aggregation. At a molar ratio of 20:1, SMase-induced aggregation was fully blocked. Binding of 4F to LDL particles inhibited SMase-induced hydrolysis of LDL by 10% and prevented SMase-induced LDL aggregation. In addition, the binding of the SMase-modified LDL particles to human aortic proteoglycans was dose-dependently inhibited by pretreating LDL with 4F. The 4F stabilized apoB-100 conformation and inhibited SMase-induced conformational changes of apoB-100. Molecular dynamic simulations showed that upon binding to protein-free LDL surface, 4F locally alters membrane order and fluidity and induces structural changes to the lipid layer. Collectively, 4F stabilizes LDL particles by preventing the SMase-induced conformational changes in apoB-100 and so blocks SMase-induced LDL aggregation and the resulting increase in LDL retention.

Keywords: apolipoprotein B-100; atherosclerosis; conformation; interaction; low density lipoprotein; proteoglycans; retention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aorta / drug effects
  • Aorta / metabolism
  • Aorta / pathology
  • Apolipoprotein A-I / metabolism
  • Apolipoprotein A-I / pharmacology*
  • Apolipoprotein B-100 / metabolism*
  • Biomimetics
  • Humans
  • Lipolysis / drug effects
  • Lipoproteins, LDL / metabolism*
  • Peptides / metabolism
  • Peptides / pharmacology*
  • Sphingomyelin Phosphodiesterase / antagonists & inhibitors
  • Sphingomyelin Phosphodiesterase / metabolism*

Substances

  • Apolipoprotein A-I
  • Apolipoprotein B-100
  • Lipoproteins, LDL
  • Peptides
  • apolipoprotein A-I mimetic peptide 4F
  • Sphingomyelin Phosphodiesterase